Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ventyx Biosciences, Inc.

2.07
-0.0750-3.50%
Post-market: 2.100.0350+1.69%19:50 EDT
Volume:984.61K
Turnover:2.09M
Market Cap:146.95M
PE:-1.18
High:2.20
Open:2.15
Low:2.06
Close:2.14
Loading ...

Ventyx Biosciences (VTYX) Gets a Hold from Stifel Nicolaus

TIPRANKS
·
23 Jun

Positive Outlook on Ventyx Biosciences Due to Promising Developments in Neuro-Inflammatory Treatments

TIPRANKS
·
18 Jun

Positive Buy Rating for Ventyx Biosciences Driven by Promising Phase 2a Trial Results and Strong Financial Position

TIPRANKS
·
18 Jun

Sector Update: Health Care Stocks Fall in Afternoon Trading

MT Newswires Live
·
18 Jun

H.C. Wainwright Sticks to Their Hold Rating for Ventyx Biosciences (VTYX)

TIPRANKS
·
18 Jun

BRIEF-Ventyx Biosciences Announces Positive Data From Its Phase 2A Trial Evaluating Vtx3232 In Patients With Early-Stage Parkinson’S Disease

Reuters
·
17 Jun

Ventyx announces Phase 2a study of VTX3232 accomplished primary objective

TIPRANKS
·
17 Jun

Ventyx Biosciences Announces Positive Top-Line Data From Its Phase 2a Safety and Biomarker Trial Evaluating Vtx3232 in Patients With Early-Stage Parkinson’s Disease

THOMSON REUTERS
·
17 Jun

Ventyx Biosciences Inc - Vtx3232 Phase 2 Trial in Obesity and Cardiometabolic Risk Factors Results Expected H2 2025

THOMSON REUTERS
·
17 Jun

Ventyx Biosciences Inc - Vtx3232 Shows Significant Reductions in Nlrp3-Related Biomarkers

THOMSON REUTERS
·
17 Jun

Ventyx Biosciences Inc - Vtx3232 Study Meets Primary Goal of Safety and Tolerability

THOMSON REUTERS
·
17 Jun

Ventyx Biosciences Inc. Conducted Annual Stockholders Meeting

Reuters
·
11 Jun

Ventyx Biosciences: Strategic Investment by Sanofi Highlights Promising Prospects and Innovative Approach

TIPRANKS
·
22 May

Morgan Stanley Sticks to Its Hold Rating for Ventyx Biosciences (VTYX)

TIPRANKS
·
19 May

Piper Sandler Sticks to Its Buy Rating for Ventyx Biosciences (VTYX)

TIPRANKS
·
09 May

Ventyx Biosciences Q1 EPS $(0.39) Beats $(0.49) Estimate

Benzinga
·
09 May

Ventyx Biosciences Reports Q1 2025 Results: Net Loss Narrows to $27.4M, Down from $38.6M in 2024, as R&D Expenses Decrease

Reuters
·
09 May

BRIEF-Ventyx Biosciences Q1 EPS USD -0.39

Reuters
·
09 May

Ventyx Biosciences Q1 EPS USD -0.39

THOMSON REUTERS
·
09 May

Press Release: Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

Dow Jones
·
01 Apr